Outcomes of patients with residual ATM kinase activity and with absent kinase activity. (A) EFS in patients with absent ATM kinase activity vs those with residual activity (102 treated patients with available data). (B) Cumulative incidence of TRM in patients with absent ATM kinase activity vs those with residual activity (102 treated patients with available data). (C) Patterns of cancer therapy failure for patients with absent ATM kinase activity vs those with residual activity. P values are based on a comparison performed at a predefined time point of 4 years from cancer diagnosis based on log-log transformation.